Seeking Clues to Hologic (HOLX) Q3 Earnings? A Peek Into Wall Street Projections for Key Metrics

Core Viewpoint - Hologic (HOLX) is expected to report a slight decline in quarterly earnings and revenues compared to the previous year, with analysts maintaining their consensus estimates over the last month [1][2]. Revenue Projections - Total revenues are forecasted to be $1.01 billion, reflecting a year-over-year decrease of 0.4% [1]. - Specific revenue estimates include: - GYN surgical revenues projected at $179.82 million, a year-over-year increase of 7.9% [4]. - Diagnostics - Molecular diagnostics expected to reach $316.12 million, up 1.8% from the prior year [4]. - Diagnostics - Blood screening anticipated at $5.65 million, down 28.5% year-over-year [5]. - Breast health - Breast imaging revenues estimated at $277.39 million, a decrease of 10.3% [5]. - Total Diagnostics revenues projected at $437.46 million, indicating a decline of 0.8% [5]. - Skeletal health revenues expected to be $25.34 million, up 33.4% from the previous year [6]. - Diagnostics - Cytology and perinatal forecasted at $117.36 million, down 4% [6]. - Total Breast health revenues estimated at $363.15 million, a decrease of 5.7% [6]. - Breast health - Interventional breast solutions projected at $85.76 million, an increase of 13.1% [7]. - Service and other revenues expected to be $202.73 million, up 1.3% [7]. - Product revenues anticipated at $801.50 million, down 1.2% from the prior year [7]. Stock Performance - Hologic shares have increased by 1.5% over the past month, compared to a 4.6% increase in the Zacks S&P 500 composite [8]. - The company holds a Zacks Rank 4 (Sell), indicating expectations of underperformance relative to the overall market in the near term [8].